Dawwas Muhammad F, Lewsey James D, Watson Christopher J, Gimson Alexander E
Liver Transplant Unit, Cambridge University Hospitals NHS Foundation Trust, Addenbrooke's Hospital, Hills Road, Cambridge, United Kingdom.
Transplantation. 2009 Aug 15;88(3):402-10. doi: 10.1097/TP.0b013e3181aed8e4.
Potassium plays a key role in human metabolism in both health and disease. The impact of recipient serum potassium concentration [K] on mortality after liver transplantation has not been described previously.
We assessed the effect of recipient [K] on the survival of adult first single-organ liver transplant recipients in the United Kingdom and Ireland between March 1, 1994, and February 28, 2007 (n=5942), adjusting for recipient, donor, and graft characteristics.
The overall risk-adjusted mortality significantly varied by [K], being higher among hyperkalemic ([K]>5.0 mmol/L) recipients (n=424, hazard ratio [HR] 1.38, 95% confidence interval [CI] 1.01-1.88) and those with [K] of 4.5-5.0 mmol/L (n=1154, HR 1.47, 95% CI 1.13-1.91), compared with hypokalemic ([K]<3.5 mmol/L) recipients (n=360). However, the excess mortality was confined to the first posttransplant year among hyperkalemic recipients (HR 1.61, 95% CI 1.10-2.35) with no significant difference thereafter (HR 1.03, 95% CI 0.62-1.73). This was also true for recipients with [K] of 4.5 to 5.0 mmol/L (< or =1 year: HR 1.70, 95% CI 1.22-2.38; >1 year: HR 1.09, 95% CI 0.71-1.66). In contrast, those with [K] of 3.5 to 3.9 mmol/L (n=1518) and [K] of 4.0-4.4 mmol/L (n=2091) had similar risk-adjusted mortality at the above time points. When [K] was used as a continuous variable in the multivariable analysis, a mmol increase in [K] was associated with an increased adjusted risk of mortality of 27% (95% CI 12%-44%) at 1 year and 19% (95% CI 7%-31%) at 5 years.
Recipient [K] is an independent predictor of death after liver transplantation. This finding could be of clinical utility in the management, risk stratification, selection, and prioritization of appropriate candidates for transplantation among patients with end-stage liver disease.
钾在人类健康与疾病的新陈代谢中均起着关键作用。此前尚未描述过受体血清钾浓度[K]对肝移植后死亡率的影响。
我们评估了1994年3月1日至2007年2月28日期间英国和爱尔兰成年首例单器官肝移植受体的[K]对其生存的影响(n = 5942),并对受体、供体和移植物特征进行了校正。
经风险调整后的总体死亡率因[K]而有显著差异,高钾血症([K]>5.0 mmol/L)受体(n = 424,风险比[HR] 1.38,95%置信区间[CI] 1.01 - 1.88)以及[K]为4.5 - 5.0 mmol/L的受体(n = 1154,HR 1.47,95% CI 1.13 - 1.91)的死亡率高于低钾血症([K]<3.5 mmol/L)受体(n = 360)。然而,高钾血症受体的额外死亡率仅限于移植后的第一年(HR 1.61,95% CI 1.10 - 2.35),此后无显著差异(HR 1.03,95% CI 0.62 - 1.73)。[K]为4.5至5.0 mmol/L的受体也是如此(≤1年:HR 1.70,95% CI 1.22 - 2.38;>1年:HR 1.09,95% CI 0.71 - 1.66)。相比之下,[K]为3.5至3.9 mmol/L(n = 1518)和[K]为4.0 - 4.4 mmol/L(n = 2091)的受体在上述时间点的风险调整后死亡率相似。在多变量分析中,当将[K]作为连续变量时,[K]每增加1 mmol,1年时调整后的死亡风险增加27%(95% CI 12% - 44%),5年时增加19%(95% CI 7% - 31%)。
受体[K]是肝移植后死亡的独立预测因素。这一发现可能在终末期肝病患者的管理、风险分层、选择以及合适移植候选人的优先排序方面具有临床实用性。